Navigation Links
Regeneron Pharmaceuticals and BioMed Realty Trust Host Ribbon-Cutting Ceremony at the Landmark at Eastview
Date:10/6/2009

for Subcutaneous Use, its first commercialized product, Regeneron has therapeutic candidates in clinical trials for the potential treatment of cancer, eye diseases, inflammatory diseases, and pain, and has preclinical programs in other diseases and disorders. Additional information about Regeneron and recent news releases are available on Regeneron's Web site at www.regeneron.com.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed owns or has interests in 69 properties, representing 114 buildings with approximately 10.5 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associa
'/>"/>

SOURCE BioMed Realty Trust, Inc.; Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. BioSpace to Host Regeneron Pharmaceuticals Career Fair in Whippany, New Jersey
2. Cellectis and Regeneron Sign an Agreement Over the use of Homologous Recombination Technology
3. BioMed Realty Trust Expands Landmark Leases With Regeneron Pharmaceuticals
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Carahsoft and CDS Federal Services have ... at 2pm EST (11am PST), “Natural Language Processing: Converting ... how technology can turn raw, heterogeneous data into actionable ... The online webinar will last approximately one hour. , ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... of Alliqua, Inc. (OTCQB: ALQA). Alliqua is an emerging ... to serve the wound care market. , Free report ... was restructured with a seasoned management team and Board, ...
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... Calif., April 4, 2011 MedeAnalytics announced today the ... proposed rule for the Medicare Shared Savings Program issued ... March 31, 2011. (Logo:   http://photos.prnewswire.com/prnh/20100621/SF23660LOGO ) ... Summary and Analysis of the Proposed Rule," covers a ...
... reveals a potentially highly effective treatment for heterotopic ossification ... bone tissue. HO comes in two main forms—one that ... wounded military personnel and surgery patients and is triggered ... animal study by developmental biologists shows that a drug ...
... SAN DIEGO, April 1, 2011 Optimer Pharmaceuticals, Inc. (NASDAQ: ... 2011 the Compensation Committee of its Board of Directors approved ... of 258,000 shares of common stock to 7 new employees. ... option has an exercise price per share equal to $11.83, ...
Cached Biology Technology:ACO Proposed Rule Simplified: MedeAnalytics Releases Comprehensive White Paper 2Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 2Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 3Potential Treatment Found for Debilitating Bone Disease in Wounded Soldiers and Children 4Optimer Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 2
(Date:4/17/2014)... is the process whereby the genetic information of ... as proteins, which have numerous different functions in ... important intermediary during gene expression, by relating the ... involved in manufacturing proteins. , By examining ... present in an organism at a given time, ...
(Date:4/17/2014)... Scientists have uncovered a new way the immune system ... aid efforts to use immune cells to treat illness. ... have the immunological equivalent of "neighborhood police" specialized ... single organ, instead of an entire city, the body. ... St. Louis have shown that the liver, skin and ...
(Date:4/17/2014)... derive from Charles Darwin, whose ideas in turn ... the 19th century, a period when landowners vigorously ... from Darwin that we inherit the ideas that ... species and total human control over breeding and ... industrial setting has been applied too broadly in ...
Breaking Biology News(10 mins):Rapid and accurate mRNA detection in plant tissues 2Some immune cells defend only 1 organ 2The story of animal domestication retold 2The story of animal domestication retold 3The story of animal domestication retold 4
... time that embryonic stem (ES) cells cultured in the ... viable offspring. The research, published in the July issue ... studies, including investigation of mechanisms involved in sperm production ... Previous studies have shown that ES cells grown in ...
... San Diego have developed what they call a "Smart ... new drugs for toxic interactions or identify cells in ... blood. , Their invention, described in the June 20 ... the American Chemical Society, uses porous silicon crystals filled ...
... lend new insight into the mechanism of genomic imprinting, ... in the silencing of an imprinted gene cluster in ... gene based upon which parent it has been inherited ... human disorders, Prader-Willi and Angelman syndromes, result from the ...
Cached Biology News:Sperm created in the laboratory from embryonic stem cells produce viable progeny 2UCSD researchers develop 'smart petri dish' 2UCSD researchers develop 'smart petri dish' 3
... Continuing a tradition of progressive centrifuge ... CL3 series. The Centra-CL3 and Centra-CL3R (refrigerated) ... todays laboratory., Quality Control Over Sample ... and lock up to 99 protocols and ...
PP2B-Abeta (C-20)...
... isoprostanes produced from arachidonic acid during lipid peroxidation. ... rat. 8-iso PGE2 inhibits U-46619 or I-BOP-induced platelet ... µM, respectively. When infused into the renal artery ... mg/kg/min, 8-iso PGE2 decreases the GFR and renal ...
SMVT (N-14)...
Biology Products: